Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Revue Medicale Suisse|April 23, 2011
[High frequency of cutaneous adverse effects under infliximab. Geneva experience, 1999-2008]Floriane Seydtaghia, Philippe De Saussure, Antoine Hadengue
Journal of Medical Case Reports|January 16, 2009
Perforated Meckel's diverticulitis complicating active Crohn's ileitis: a case reportFrank Schwenter, Pascal Gervaz, Philippe de Saussure, et al.
World Journal of Gastroenterology|May 1, 2007
Severe delayed complication after percutaneous endoscopic colostomy for chronic intestinal pseudo-obstruction: a case report and review of the literatureDavid Bertolini, Philippe De Saussure, Michael Chilcott, et al.
Gastroenterologie Clinique Et Biologique|June 2, 2007
Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice settingPhilippe de Saussure, Pierre Clerson, Pierre-Louis Prost, et al.
Plos One|March 4, 2016
Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?Valérie Pittet, Carla Vaucher, Michel H Maillard, et al.
Scandinavian Journal of Gastroenterology|March 13, 2014
Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patientsValérie Pittet, Gerhard Rogler, Christian Mottet, et al.
Digestion|January 23, 2010
Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's diseaseCristina Nichita, Marc Stelle, Stephan Vavricka, et al.
Inflammatory Bowel Diseases|January 13, 2009
Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancyJulien Branche, Antoine Cortot, Arnaud Bourreille, et al.
Gastroenterology|July 10, 2002
Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trialJean Louis Frossard, Laurent Spahr, Pierre Edouard Queneau, et al.
Inflammatory Bowel Diseases|December 17, 2009
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS surveyAlain M Schoepfer, Stephan R Vavricka, Janek Binek, et al.
Pageof 2